A Phase II, double‐blind, randomized, parallel group, dose‐finding study of the safety and tolerability of darexaban compared with warfarin in patients with non‐valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL‐2)

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 8, 2015-08 ,pp. : 1405-1413

John Wiley & Sons Inc

Access to resources Recommend Favorite

The relationship between the pre‐admission CHA2DS2‐VASc score and proximal artery occlusion in patients with acute stroke and atrial fibrillation

By  

EUROPEAN JOURNAL OF NEUROLOGY, Vol. 22, Iss. 7, 2015-07 ,pp. : 1081-1087

John Wiley & Sons Inc

Access to resources Recommend Favorite

Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US

By Schoof Nils   Schnee Janet   Schneider Gary   Gawlik Melissa   Zint Kristina   Clemens Andreas   Bartels Dorothee B.  

Current Medical Research and Opinion, Vol. 30, Iss. 5, 2014-05 ,pp. : 795-804

Informa Healthcare

Access to resources Recommend Favorite

The Relationships between Atrial Electromechanical Delay and CHA2DS2‐VASc Score in Patients Diagnosed with Paroxysmal AF

By  

ECHOCARDIOGRAPHY (ELECTRONIC), Vol. 32, Iss. 9, 2015-09 ,pp. : 1359-1366

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?

By Laliberté François   Pilon Dominic   Raut Monika K.   Nelson Winnie W.   Olson William H.   Germain Guillaume   Schein Jeff R.   Lefebvre Patrick  

Current Medical Research and Opinion, Vol. 30, Iss. 4, 2014-04 ,pp. : 645-653

Informa Healthcare

Access to resources Recommend Favorite